Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1998 2
1999 4
2000 3
2001 5
2002 10
2003 6
2004 11
2005 18
2006 15
2007 19
2008 49
2009 73
2010 102
2011 149
2012 144
2013 194
2014 222
2015 256
2016 283
2017 296
2018 291
2019 267
2020 340
2021 335
2022 307
2023 337
2024 165

Text availability

Article attribute

Article type

Publication date

Search Results

3,388 results

Results by year

Filters applied: . Clear all
Page 1
Response and Resistance to BCR-ABL1-Targeted Therapies.
Braun TP, Eide CA, Druker BJ. Braun TP, et al. Cancer Cell. 2020 Apr 13;37(4):530-542. doi: 10.1016/j.ccell.2020.03.006. Cancer Cell. 2020. PMID: 32289275 Free PMC article. Review.
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. ...In contrast, responses to TKI treatment are short lived in advanced phases …
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for success …
BCR-ABL1-like B-Acute Lymphoblastic Leukemia/Lymphoma: A Comprehensive Review.
Jain S, Abraham A. Jain S, et al. Arch Pathol Lab Med. 2020 Feb;144(2):150-155. doi: 10.5858/arpa.2019-0194-RA. Epub 2019 Oct 23. Arch Pathol Lab Med. 2020. PMID: 31644323 Free article. Review.
.-: In the 2016 update of the World Health Organization (WHO) classification of hematopoietic neoplasms, BCR-ABL1-like B-acute lymphoblastic leukemia/lymphoma (B-ALL) is added as a new provisional entity that lacks the BCR-ABL1 translocation but shows a patte …
.-: In the 2016 update of the World Health Organization (WHO) classification of hematopoietic neoplasms, BCR-ABL1-like B-acute …
Chronic Myeloid Leukemia: Beyond BCR-ABL1.
Zhou T, Medeiros LJ, Hu S. Zhou T, et al. Curr Hematol Malig Rep. 2018 Dec;13(6):435-445. doi: 10.1007/s11899-018-0474-6. Curr Hematol Malig Rep. 2018. PMID: 30370478 Review.
Over the past decades, many research efforts were devoted to elucidating the leukemogenic mechanisms of BCR-ABL1 and developing novel TKIs. More recent studies have attempted to answer new questions that have emerged in the TKI era, such as the cytogenetic and molecular ba …
Over the past decades, many research efforts were devoted to elucidating the leukemogenic mechanisms of BCR-ABL1 and developing novel …
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. Burslem GM, et al. Cancer Res. 2019 Sep 15;79(18):4744-4753. doi: 10.1158/0008-5472.CAN-19-1236. Epub 2019 Jul 16. Cancer Res. 2019. PMID: 31311809 Free PMC article.
Notably, GMB-475 inhibited the proliferation of certain clinically relevant BCR-ABL1 kinase domain point mutants and further sensitized Ba/F3 BCR-ABL1 cells to inhibition by imatinib, while demonstrating no toxicity toward Ba/F3 parental cells. ...GMB-475 degraded B …
Notably, GMB-475 inhibited the proliferation of certain clinically relevant BCR-ABL1 kinase domain point mutants and further sensitiz …
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, Palmer M, Leary RJ, Chiang DY, Sellers WR, Michor F, Cooke VG, Korn JM, Stegmeier F. Bhang HE, et al. Nat Med. 2015 May;21(5):440-8. doi: 10.1038/nm.3841. Epub 2015 Apr 13. Nat Med. 2015. PMID: 25849130
Resistance to cancer therapies presents a significant clinical challenge. Recent studies have revealed intratumoral heterogeneity as a source of therapeutic resistance. ...Thus, ClonTracer barcoding may be a valuable tool for optimizing therapeutic regimens with the goal o …
Resistance to cancer therapies presents a significant clinical challenge. Recent studies have revealed intratumoral heterogeneity as …
Depression accelerates the development of gastric cancer through reactive oxygen species-activated ABL1 (Review).
Huang T, Zhou F, Wang-Johanning F, Nan K, Wei Y. Huang T, et al. Oncol Rep. 2016 Nov;36(5):2435-2443. doi: 10.3892/or.2016.5127. Epub 2016 Sep 23. Oncol Rep. 2016. PMID: 27666407 Review.
Depression is a common symptom among gastric cancer (GC) patients and serves as a potential indication of poor prognosis and advanced cancer clinical stage. ...Recent studies have revealed that GC patients with depression are under high levels of oxidative stress (O …
Depression is a common symptom among gastric cancer (GC) patients and serves as a potential indication of poor prognosis and advanced …
VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer.
Kim MH, Yang GE, Jeong MS, Mun JY, Lee SY, Nam JK, Choi YH, Kim TN, Leem SH. Kim MH, et al. BMC Med Genomics. 2021 May 5;14(1):121. doi: 10.1186/s12920-021-00968-1. BMC Med Genomics. 2021. PMID: 33952249 Free PMC article.
BACKGROUND: ABL1 is primarily known as a leukemia-related oncogene due to translocation, but about 2.2% of ABL1 mutations have been identified in bladder cancer, and high expression in solid cancer has also been detected. ...CONCLUSIONS: Therefore, the …
BACKGROUND: ABL1 is primarily known as a leukemia-related oncogene due to translocation, but about 2.2% of ABL1 mutations have …
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Short NJ, et al. Am J Hematol. 2023 Aug;98(8):1196-1203. doi: 10.1002/ajh.26949. Epub 2023 May 15. Am J Hematol. 2023. PMID: 37183966
In a separate cohort of prospectively collected clinical samples, 11 of 65 patients (17%) with Ph+ ALL who achieved NGS MRD negativity had detectable BCR::ABL1 by PCR, and none of these patients relapsed. Relapse-free survival and overall survival were similar in patients …
In a separate cohort of prospectively collected clinical samples, 11 of 65 patients (17%) with Ph+ ALL who achieved NGS MRD negativity had d …
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens.
Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, Liu XS. Li W, et al. Genome Biol. 2014;15(12):554. doi: 10.1186/s13059-014-0554-4. Genome Biol. 2014. PMID: 25476604 Free PMC article.
MAGeCK also detected cell type-specific essential genes, including BCR and ABL1, in KBM7 cells bearing a BCR-ABL fusion, and IGF1R in HL-60 cells, which depends on the insulin signaling pathway for proliferation....
MAGeCK also detected cell type-specific essential genes, including BCR and ABL1, in KBM7 cells bearing a BCR-ABL fusion, and IGF1R in …
The international consensus classification of eosinophilic disorders and systemic mastocytosis.
Wang SA, Orazi A, Gotlib J, Reiter A, Tzankov A, Hasserjian RP, Arber DA, Tefferi A. Wang SA, et al. Am J Hematol. 2023 Aug;98(8):1286-1306. doi: 10.1002/ajh.26966. Epub 2023 Jun 7. Am J Hematol. 2023. PMID: 37283522 Review.
The category has been expanded to include ETV6::ABL1 and FLT3 fusions, and to accept PCM1::JAK2 and its genetic variants as formal members. The overlaps and differences between M/LN-eo-TK and BCR::ABL1-like B-lymphoblastic leukemia (ALL)/de novo T-ALL sharing the sa …
The category has been expanded to include ETV6::ABL1 and FLT3 fusions, and to accept PCM1::JAK2 and its genetic variants as formal me …
3,388 results